Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure - Are they important for doctors?

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 740-751

  Holecki, Michał ^a   Szewieczek, Jan ^a   Chudek, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

ACE I; Additional therapeutic effects

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHINAPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFECT; EVIDENCE BASED MEDICINE; HEART PROTECTION; HUMAN; MEDICAL SPECIALIST; PHYSICIAN ATTITUDE; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; TREATMENT INDICATION;

EID: 80051503640     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70586-2     Document Type: Article

References (54)

1. Abdulla J, Barlera S, Latini R, Kjoller-Hansen L, Sogaard P, Christensen E, Kober L, Torp-Pedersen C: A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail, 2007, 9, 129-135. (Pubitemid 46394070)
2. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 2000, 283, 1967-1975.
3. Bauriedel G, Skowasch D, Schneider M, Andrié R, Jabs A, Lüderitz B: Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J, 2003, 145, 343-348. (Pubitemid 36207958)
4. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I et al.: A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J, 2006, 27, 2667-2674. (Pubitemid 44729867)
5. Chrysant SG: Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J, 1998, 135, 21-30.
6. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens, 1992, 5, 95-110.
7. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R et al.: (ASCOT Investigators): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366, 895-906. (Pubitemid 41265663)
8. Danchin N: Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization? Arch Cardiovasc Dis, 2009, 102, 81-83.
9. Dzau, VJ: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med, 1993, 153, 937-942.
10. Fagard RH, Celis H, Thijs L, Wouters S: Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension, 2009, 54, 1084-1091.
11. Fenster BE, Tsao PS, Rockson SG: Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J, 2003, 146, 218-226. (Pubitemid 36951764)
12. Fogari R, Malamani GD, Zoppi A, Mugellini A, Rinaldi A, Vanasia A, Preti P: Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens, 2003, 17, 207-212. (Pubitemid 36388805)
13. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens, 2006, 19, 1293-1299.
14. Fox KM (EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators): Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788. (Pubitemid 37093919)
15. Gainer, JV, Morrow, JD, Loveland, A, King D, Brown N: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med, 1998, 18, 1285-1292. (Pubitemid 28496194)
16. Goodfriend, TL, Elliot, ME, Catt, KJ: Angiotensin receptors and their antagonists [review]. N Engl J Med, 1996, 334, 1649.
17. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico: GISSI-3: Effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 1994, 343, 1115-1122.
18. Gryglewski RJ, Mackiewicz Z: Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo. Pharmacol Rep, 2010, 62, 462-467.
19. Hornig B, Kohler C, Drexler H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation, 1997, 95, 1115-1118. (Pubitemid 27097818)
20. Heart Outcomes Prevention Evaluation Study Investigators: Effect of an angiotensin converting-enzyme inhibitor, rampirii, on cardiovascular, events in high-risk patients. N Engl J Med, 2000, 342, 145-153.
21. ISIS-4 Collaborative group: Fouth International Study of Infarct Survival: a randomized factorial trial assessing early captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patients with suspected myocardial infarction. Lancet, 1995, 345, 669-685.
22. Kifor I, Moore TJ, Fallo F, Sperling E, Chiou CY, Menachery A, Williams GH: Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically digested cells of the zona glomerulosa. Endocrinology, 1991, 129, 823-831.
23. Kiranbir J, Sumit R, Finlay A.: The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ, 2008, 178, 576-584.
24. Kintscher U. ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. J Hypertens, Suppl, 2009, 27, 36-39.
25. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J et al.: A clinical trial of the angiotensin-converting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med, 1995, 333, 1670-1676. (Pubitemid 26001955)
26. Kumar R, Singh VP, Baker KM: The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens, 2008, 17, 168-173. (Pubitemid 351253042)
27. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A et al.: SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation, 2001, 103, 919-925. (Pubitemid 32183795)
28. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
29. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, Ishii M: Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol, 1999, 26, 797-802. (Pubitemid 29476994)
30. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein K: Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature, 1991, 351, 233-236. (Pubitemid 21896571)
31. Naftilan AJ, Zuo WM, Ingelfinger J, Ryan TJ Jr, Pratt RE, Dzau VJ: Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest, 1991, 88, 1300-1311.
32. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L et al.; CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA, 2004, 292, 2217-2225.
33. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007, 370, 829-840.
34. Pepine CJ, Rouleau JL, Annis K, Ducharme A, Ma P, Lenis J, Davies R et al.; QUASAR Study Group: Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol, 2003, 42, 2049-2059. (Pubitemid 37549883)
35. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 2000, 102, 1503-1510.
36. Quan, A, Baum, M: Effect of luminal angiotensin II receptor antagonists on proximal tubule transport. Am J Hypertens, 1999, 12, 499-503. (Pubitemid 29238411)
37. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, Lamas GA et al.: Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation, 1994, 90, 1731-1738. (Pubitemid 24320919)
38. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I et al.: (HOPE Investigators): Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J, 2007, 154, 448-453. (Pubitemid 47271928)
39. Schiffrin EL: Remodeling of resistance arteries in human hypertension: effects of cilazapril, an angiotensin-I-converting enzyme inhibitor. Cardiology, 1995, 86, 16-22.
40. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA, 1996, 275, 1507-1513. (Pubitemid 26140765)
41. Schölkens BA, Landgraf W: ACE inhibition and atherogenesis. Can J Physiol Pharmacol, 2002, 80, 354-359. (Pubitemid 34451253)
42. Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin SE, Talsness CE, Dzau VJ: Evidence for tissue specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest, 1992, 90, 1523-1529.
43. Semple PF: Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J Hypertens, Suppl, 1995, 13, 17-21.
44. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 1993, 342, 821-828.
45. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of Cooperative North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med, 1987, 316, 1429-1435.
46. The DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med, 2006, 355, 1551-1562.
47. The SOLVD Investigators: Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med, 1992, 327, 685-691.
48. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY et al.: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J, 2003, 24, 2090-2098.
49. Van den Heuvel AF, Dunselman PH, Kingma T, Verhorst P, Boomsma F, van Gilst WH, van Veldhuisen DJ: Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol, 2001, 37, 470-474.
50. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension, 2005, 46, 386-392. (Pubitemid 41099174)
51. Wagner, C, Jensen, BL, Kramer, BK, Kurtz, A. Control of the renal renin system by local factors. Kidney Int, 1998, 54, Suppl 67, S78.
52. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M: Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke, 2006, 37, 1933-1940. (Pubitemid 44297754)
53. Wiȩcek A, Chudek J, Kokot F: Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications. Nephrol Dial Transplant, 2003, 18, 16-20.
54. Wilkes BM, Mento PF, Pearl AR, Hollander AM, Mossey RT, Bellucci A Bluestone PA, Mailloux LU: Plasma angiotensins in anephric humans: Evidence for an extrarenal angiotensin system. J Cardiovasc Pharmacol, 1991, 17, 419-423.